FDA Approves AMMONIA N 13 — Washington University School of Medicine

# FDA Approval Newswire Washington University School of Medicine has received FDA approval for AMMONIA N-13 (NH3N13), an intravenous diagnostic radiopharmaceutical that expands the institution's positron emission tomography (PET) imaging capabilities for hepatic and neurological disorder assessment. The approval of this diagnostic agent positions Washington University to capture additional market share in the specialized nuclear medicine imaging sector, particularly for institutions seeking advanced ammonia metabolism diagnostic tools.